Genethon appoints new president
This article was originally published in Scrip
Executive Summary
Genethon (France) has nominated Yves Champey president of its AFM (French Muscular Dystrophy Association) laboratory, succeeding Bernard Barataud. Mr Champey co-founded Genethon in 1990, and as president will implement clinical trial programmes, develop innovative biotherapies for rare diseases and reinforce Genethon's position as a not-for-profit R&D company. Mr Champey was previously responsible for drug development within Pfizer and Rhône-Poulenc Rorer, was president of the AFM, and helped create the Drug for Neglected Diseases Initiative (DNDi), of which he was president from 2003 to 2007.